Brainsway Ltd. (BWAY) stock
Close on Nov 12, 2026Market cap $401.45MP/E 56.9Yield –
Brainsway Ltd. grew revenue 27.3% to $52.23M over fiscal 2025. Operating income rose 210.8% to $4.32M, moving the operating margin from 3.4% to 8.3%. At the latest close the market valued the company at $401.45M, 56.9 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $401.45M
- P/E ratio
- 56.9
- Price to sales
- 7.69
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $52.23M
- EPS, diluted
- $0.18
Trading
- Previous close
- $11.24
- Open
- $10.71
- Day's range
- $10.20 – $10.95
- Volume
- 203,752
- Average volume (20 days)
- 116,257
- Beta (5 years)
- 1.28
- 52-week range
- $7.13 – $17.40
- RSI (14 days)
- 38.4
- Volatility (1 year)
- 55.1%
- Relative volume
- 1.73×
- WACC
- 11.3%
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | BWAY | S&P 500 | Difference | BWAY per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -10.6% | -2.7% | −7.9 pts | ||
| 3 months | -38.3% | -1.7% | −36.5 pts | ||
| Year to date | +7.8% | +11.9% | −4.1 pts | ||
| 1 year | +29.9% | +12.0% | +17.9 pts | ||
| 3 years | +427.0% | +78.2% | +348.8 pts | +74.0% | +21.2% |
| 5 years | +158.0% | +73.2% | +84.8 pts | +20.9% | +11.6% |
| 10 years | +102400.0% | +309.6% | +102090.4 pts | +100.0% | +15.1% |
Ten years at a glance
Fiscal years 2016 to 2025, USD
Revenue
Gross profit
Operating income
EPS, diluted
Free cash flow
Press releases
Releases Brainsway filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Brainsway
Surgical & Medical Instruments & Apparatus
BrainsWay Ltd. develops and commercializes medical devices centered on its proprietary Deep Transcranial Magnetic Stimulation technology. The company focuses on non-invasive neurostimulation systems designed to treat psychiatric and neurological conditions, alongside related hardware components and system enhancements. Its business encompasses direct product sales, system leasing, and strategic collaboration arrangements. The company primarily serves healthcare providers, including physicians, treatment operators, and clinical facilities, while interacting with third-party payors such as commercial insurers and Medicare.
Company profile, executives and historyBrainsway stock: common questions
What is Brainsway's stock price?
BWAY closed at $10.25 on Nov 12, 2026, down 8.81% on the day. Over the past 52 weeks it traded between $7.13 and $17.40.
What is Brainsway's market cap?
Brainsway was worth $401.45M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is BWAY's P/E ratio?
BWAY trades at 56.9 times earnings, based on diluted earnings per share of $0.18 over fiscal 2025.
How much revenue does Brainsway make?
Brainsway reported revenue of $52.23M for fiscal 2025, up 27.3% from a year earlier.
Does Brainsway pay a dividend?
No. Brainsway has not paid a cash dividend over the last twelve months.
How has BWAY stock performed over the past year?
Including dividends, BWAY returned +29.9% over the past year, against +12.0% for the S&P 500.
Who are Brainsway's competitors?
Companies most similar to Brainsway by business, industry and size include CLPT, STIM, CVRX, NPCE, LNSR.
See a number that looks wrong?